In terms of combinational treatment, the phase III prospective, randomized clinical trial KEYNOTE-789 has released its preliminary results in the most recently, results of which suggested that the addition of pembrolizumab to chemotherapy fail to prolong PFS or OS in TKI-resistant EGFR-mutant NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.